Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O'Reilly, DY Oh, N Dhani, DJ Renouf… - JAMA …, 2019 - jamanetwork.com
Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination
therapy in patients with mPDAC. Objective To evaluate the safety and efficacy of the anti–PD-
L1 (programmed death-ligand 1) antibody using either durvalumab monotherapy or in
combination with the anticytotoxic T-lymphocyte antigen 4 antibody using durvalumab plus
tremelimumab therapy in patients with mPDAC. Design, Setting, and Participants Part A of …
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination
therapy in patients with mPDAC. Objective To evaluate the safety and efficacy of the anti–PD-
L1 (programmed death-ligand 1) antibody using either durvalumab monotherapy or in
combination with the anticytotoxic T-lymphocyte antigen 4 antibody using durvalumab plus
tremelimumab therapy in patients with mPDAC. Design, Setting, and Participants Part A of …